FOXO Technologies Reports Strong Q1 Revenue Growth, Narrows Loss, Announces 1-for-3,000 Reverse Split
FOXOD filed a Earnings and Guidance on elevated volume (6.8× avg).
Summary
FOXO Technologies reported significantly improved Q1 results, with net revenues rising to $5.1 million from $3.2 million year-over-year and operating loss narrowing substantially to $0.3 million from $1.5 million. The company also completed a massive 1-for-3,000 reverse stock split, a move aimed at improving liquidity and attracting institutional investors. Further strategic actions include converting $7.8 million of preferred stock into non-convertible debt to limit future dilution and granting an exclusive ten-year license for epigenetics IP, which includes a 3% royalty and potential 40% retained ownership. These combined actions represent a significant restructuring and operational turnaround effort.
At the time of this announcement, FOXOD was trading at $0.14 on OTC in the Life Sciences sector, with a market capitalization of approximately $197.7K. The 52-week trading range was $0.00 to $1,100.38. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.